Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Biocept Inc is a diagnostics & research business based in the US. Biocept shares (BIOC) are listed on the NASDAQ and all prices are listed in US Dollars. Biocept employs 104 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $2.86 |
|---|---|
| 52-week range | $2.98 - $8.38 |
| 50-day moving average | $3.73 |
| 200-day moving average | $4.03 |
| Wall St. target price | $13.00 |
| PE ratio | 13.79 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.22 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.86 from 2022-01-26
| 1 week (2022-01-21) | -5.30% |
|---|---|
| 1 month (2021-12-28) | -21.86% |
| 3 months (2021-10-28) | -25.13% |
| 6 months (2021-07-28) | -31.58% |
| 1 year (2021-01-28) | -51.53% |
|---|---|
| 2 years (2020-01-28) | 778.11% |
| 3 years (2019-01-28) | 35.55% |
| 5 years (2017-01-27) | 83.33% |
Valuing Biocept stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biocept's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biocept's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Biocept shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Biocept's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.7 million.
The EBITDA is a measure of a Biocept's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $65.8 million |
|---|---|
| Operating margin TTM | 5.15% |
| Gross profit TTM | $6.1 million |
| Return on assets TTM | 4.47% |
| Return on equity TTM | 10.1% |
| Profit margin | 4.71% |
| Book value | $2.40 |
| Market capitalisation | $50.9 million |
TTM: trailing 12 months
We're not expecting Biocept to pay a dividend over the next 12 months.
Biocept's shares were split on a 1:10 basis on 7 September 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biocept shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Biocept shares which in turn could have impacted Biocept's share price.
Over the last 12 months, Biocept's shares have ranged in value from as little as $2.98 up to $8.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biocept's is 0.4465. This would suggest that Biocept's shares are less volatile than average (for this exchange).
Biocept, Inc. , an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus.
Five major factors contribute to the continued bull run of Bitcoin, ARK says, including growing adoption and long-term focus of investors.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
